While SKYCovione, a domestic COVID-19 vaccine, obtained approval in the UK, SK bioscience predicted that global expansion would begin in earnest after the WHO EUL listing expected next year. According to the pharmaceutical industry on the 31st, SK bioscience received official approval for SKYCovione from the British MHRA on the 26th (local time). It is a vaccine for primary vaccination (1st and 2nd) for adults over 18 years of age in England, Scotland, and Wales. It is the first overseas approval for a domestic corona vaccine. SK Bioscience is promoting WHO EUL listing and EMA sales permission. It applied for EUL listing to WHO in September of last year, and conditional permission to EMA in August of last year. It is